SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Elmer who wrote (903)1/21/2002 7:48:39 PM
From: SemiBull  Respond to of 3044
 
ON24: Biotech earnings preview, analyst expects few surprises
biz.yahoo.com



To: Elmer who wrote (903)1/21/2002 10:30:18 PM
From: Madharry  Respond to of 3044
 
the last time i read a valuation by a morgan stanley analyst it involved a target of $250 on CRGN. when i read through the analysis it was based upon a 12 year forward multiple of earnings which was then discounted. I would take these valuations with a few grains of salt. then again the analyst knows that it is not likely that he will be working for morgan stanley in 12 years or that anyone will remember what he said unless he turns out to be right.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News